Anticoagulants affect matrix metalloproteinase 9 levels in blood samples of stroke patients and healthy controls.
Clin Biochem
; 45(6): 483-9, 2012 Apr.
Article
in En
| MEDLINE
| ID: mdl-22342361
OBJECTIVES: Matrix metalloproteinase-9 (MMP-9) represents a promising marker for acute stroke management. In clinical studies MMP-9 has been quantified by ELISA using differing protocols. We aimed to establish a valid protocol by evaluation of preanalytics. DESIGN AND METHODS: Blood from stroke patients (n=28) and healthy controls (n=28) was drawn into tubes containing different anticoagulants (EDTA, citrate, lithium-heparin (heparin) and heparin with proteinase inhibitors) and processed after 0, 60 and 240 min. MMP-9 plasma protein and mRNA from mononuclear leukocytes were determined. RESULTS: In regard to anticoagulants used, samples showed different MMP-9 protein baseline values and kinetics. Stable MMP-9 protein concentrations were only measured from EDTA samples. Particularly in samples with proteinase inhibitors protein and mRNA concentrations increased over time. Kinetics did not differ between patients and controls. CONCLUSIONS: Preanalytics plays a key role for determination of MMP-9. EDTA seems to be a valid anticoagulant for MMP-9 protein measurement.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Blood Chemical Analysis
/
Heparin
/
Artifacts
/
Citric Acid
/
Stroke
/
Matrix Metalloproteinase 9
Type of study:
Guideline
/
Observational_studies
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Clin Biochem
Year:
2012
Type:
Article
Affiliation country:
Germany